Request for Information on Carbon Nanotubes (CNTs) Including Single-Walled Carbon Nanotubes (SWCNTs) and Multi-Walled Carbon Nanotubes (MWCNTs), 15985-15986 [E9-7941]
Download as PDF
Federal Register / Vol. 74, No. 66 / Wednesday, April 8, 2009 / Notices
Dated: April 3, 2009.
Edwin L. Walker,
Acting Assistant Secretary for Aging.
[FR Doc. E9–7968 Filed 4–7–09; 8:45 am]
BILLING CODE 4154–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[Docket Number NIOSH–161]
Request for Information on Carbon
Nanotubes (CNTs) Including SingleWalled Carbon Nanotubes (SWCNTs)
and Multi-Walled Carbon Nanotubes
(MWCNTs)
rwilkins on PROD1PC63 with NOTICES
AGENCY: National Institute for
Occupational Safety and Health
(NIOSH) of the Centers for Disease
Control and Prevention (CDC),
Department of Health and Human
Services (HHS).
ACTION: Notice of public comment
period.
SUMMARY: The National Institute for
Occupational Safety and Health
(NIOSH) of the Centers for Disease
Control and Prevention (CDC) intends to
evaluate the scientific data on carbon
nanotubes (CNTs) and develop
appropriate communication documents,
such as an Alert and/or Current
Intelligence Bulletin, which will convey
the potential health risks and
recommend measures for the safe
handling of these materials. NIOSH has
developed guidelines for managing the
potential health concerns associated
with occupational exposures to
engineered nanoparticles [see: https://
www.cdc.gov/niosh/topics/nanotech/
safenano/] which will provide the
framework for developing specific
recommendations for CNTs.
NIOSH is requesting information on
the following: (1) Published and
unpublished reports and findings from
in vitro and in vivo toxicity studies with
CNTs, (2) information on possible
health effects observed in workers
exposed to CNTs, (3) information on
workplaces and products in which
CNTs can be found, (4) description of
work tasks and scenarios with a
potential for exposure, (5) workplace
exposure data, and (6) information on
control measures (e.g., engineering
controls, work practices, personal
protective equipment) that are being
used in workplaces where potential
exposures to CNTs occur.
Public Comment Period: Comments
must be received by May 15, 2009.
VerDate Nov<24>2008
17:05 Apr 07, 2009
Jkt 217001
You may submit comments,
identified by docket number NIOSH–
161, by any of the following methods:
• Mail: NIOSH Docket Office, Robert
A. Taft Laboratories, MS–C34, 4676
Columbia Parkway, Cincinnati, OH
45226.
• Facsimile: (513) 533–8285.
• E-mail: nioshdocket@cdc.gov.
All information received in response
to this notice will be available for public
examination and copying at the NIOSH
Docket Office, 4676 Columbia Parkway,
Cincinnati, Ohio 45226. A complete
electronic docket containing all
comments submitted will be available
on the NIOSH Web page at https://
www.cdc.gov/niosh/docket, and
comments will be available in writing
by request. NIOSH includes all
comments received without change in
the docket, including any personal
information provided.
FOR FURTHER INFORMATION CONTACT:
Ralph D. Zumwalde, NIOSH, Robert A.
Taft Laboratories, MS–C32, 4676
Columbia Parkway, Cincinnati, OH
45226, telephone (513) 533–8320.
SUPPLEMENTARY INFORMATION:
Nanotechnology is generally defined as
the intentional manipulation of matter
to form novel structures with one or
more dimension or features less than
100 nanometers (nm). Nanotechnology
involves a wide range of chemistries
and almost unlimited types of structures
that have highly unpredictable
interactions with biological systems.
Carbon nanotubes (CNTs) are a type of
nanomaterial comprised of a sheet of
graphite (a hexagonal lattice of carbon)
rolled into a cylinder that can have a
length-to-width ratio greater than 1,000.
Carbon nanotubes are produced having
a single cylinder carbon wall (singlewalled carbon nanotubes [SWCNT]) or
having multiple walls-cylinders nested
within other cylinders (multi-walled
carbon nanotubes [MWCNT]). CNTs
range in diameter from about 1–2
nanometers for SWCNTs to dozens of
nanometers for MWCNTs with lengths
extending into the micrometer range.
There are several major techniques
used in the synthesis of CNTs. The arcevaporation technique involves passing
a current of about 50 A between two
graphite electrodes in an atmosphere of
helium in the presence of metal
catalysts (Co, Ni). The second method is
chemical vapor deposition, where
nanotubes are formed by decomposition
of a carbon-containing gas with use of
nano-sized catalytic particles usually
Fe, Co, Yt or Ni. The advantage of
catalytic synthesis over arc-evaporation
is the ability to scale-up for volume
production. The third method for
ADDRESSES:
PO 00000
Frm 00073
Fmt 4703
Sfmt 4703
15985
making CNTs, laser ablation, involves
employment of a powerful laser to
vaporize metal (Co and Ni)-graphite
targets. Of the three major processes,
chemical vapor deposition is the most
prominent one that is currently used for
CNT production.
Due to their unique physical and
chemical properties, CNTs have sparked
much research into developing novel
applications. CNTs are ideal nonbiodegradable materials; they are
stronger then steel, flexible, lightweight,
heat resistant, and have high electrical
conductivity. The market for CNTs is
estimated to grow substantially over the
next decade. They are currently used in
a variety of applications including:
Electronics, reinforced plastics, microfabrication conjugated polymer
activators, biosensors, enhanced
electron/scanning microscopy imaging
techniques, and in pharmaceutical/
biomedical devices for drug delivery
and medical diagnostics. Estimates of
the number of workers potentially
exposed to CNTs are unavailable due to
limited exposure data and its relatively
recent introduction into domestic
commerce.
The toxic nature of SWCNTs and
MWCNTs in humans is not known.
Recently published in vitro and in vivo
studies with some SWCNTs and
MWCNTs describe adverse effects
including their ability to be cytotoxic
when tested in various cell cultures, and
cause acute inflammation and early
onset of fibrosis when delivered to the
lungs of mice by pharyngeal aspiration
or inhalation. No occupational exposure
limits for CNTs have been established
by NIOSH or the Occupational Safety
and Health Administration (OSHA).
NIOSH seeks to obtain materials,
including published and unpublished
reports and research findings, to
evaluate the possible health risks of
occupational exposure to CNTs.
Examples of requested information
include, but not limited to, the
following: (1) Identification of
industries or occupations in which
exposures to CNTs may occur.
(2) Trends in the production and use
of CNTs.
(3) Description of work tasks and
scenarios with a potential for exposure
to CNTs.
(4) Workplace exposure measurement
data in various types of industries and
jobs.
(5) Case reports or other health
information demonstrating potential
health effects in workers exposed to
CNTs.
(6) Research findings from in vitro
and in vivo toxicity studies.
E:\FR\FM\08APN1.SGM
08APN1
15986
Federal Register / Vol. 74, No. 66 / Wednesday, April 8, 2009 / Notices
(7) Information on control measures
(e.g., engineering controls, work
practices, PPE) being taken to minimize
worker exposure to CNTs.
Dated: March 31, 2009.
James D. Seligman,
Chief Information Officer, Centers for Disease
Control and Prevention.
[FR Doc. E9–7941 Filed 4–7–09; 8:45 am]
BILLING CODE 4163–19–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Criteria for Vaccination Requirements
for U.S. Immigration Purposes
rwilkins on PROD1PC63 with NOTICES
AGENCY: Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice with comment period.
SUMMARY: The Centers for Disease
Control and Prevention (CDC) is seeking
public comment on a set of proposed
criteria to be used in determining which
vaccines recommended by the Advisory
Committee on Immunization Practices
(ACIP) for the general United States
population should be required for
immigrants seeking admission into the
United States or seeking adjustment of
status to that of an alien lawfully
admitted for permanent residence.
Under section 212 of the Immigration
and Nationality Act (INA) (8 U.S.C.
1182), an alien who seeks admission as
an immigrant, or who seeks adjustment
of status to one lawfully admitted for
permanent residence, must present
documentation for having received
vaccination for ‘‘vaccine-preventable
diseases, which shall include at least
the following diseases: mumps, measles,
rubella, polio, tetanus and diphtheria
toxoids, pertussis, Haemophilus
influenzae type B and hepatitis B, and
any other vaccinations against vaccinepreventable diseases recommended by
the Advisory Committee on
Immunization Practices.’’ Because the
INA explicitly requires vaccinations for
some vaccine-preventable diseases
(mumps, measles, rubella, polio, tetanus
and diphtheria toxoids, pertussis,
Haemophilus influenzae type B and
hepatitis B), CDC will continue to
require those vaccinations for
immigrants seeking admission into the
United States or seeking to adjust their
status to that of legal permanent
resident. CDC has developed specific
criteria to determine which other
vaccinations recommended by ACIP for
the general population will be required
VerDate Nov<24>2008
17:05 Apr 07, 2009
Jkt 217001
for such immigrants. Through this
notice, CDC proposes to begin use of the
following criteria:
1. The vaccine must be an ageappropriate vaccine as recommended by
ACIP for the general U.S. population,
and
2. At least one of the following:
a. The vaccine must protect against a
disease that has the potential to cause
an outbreak.1
b. The vaccine must protect against a
disease that has been eliminated in the
United States, or is in the process for
elimination in the United States.
The evolution of vaccine development
has progressed to include those
targeting specific groups and chronic
morbidity and mortality. Therefore, CDC
is now developing specific criteria to be
applied against each vaccine in lieu of
requiring all ACIP recommended
vaccines for immigration purposes. CDC
has taken a scientific, evidence-based,
public health approach in developing
these criteria, and has considered the
unique characteristics of the time and
place of the medical screening process
for U.S. immigration purposes.
Using specific scientific-based criteria
to determine the relevant vaccines
required for U.S. immigration purposes
will ensure CDC decision-making
regarding vaccination requirements is
grounded in public health necessity and
need in light of a growing list of
vaccines for infectious and noninfectious diseases.
After consideration of public
comments received through this notice,
as well as those received during an
ACIP meeting held at CDC February 25–
26, 2009, CDC will publish a notice
regarding implementation of the final
criteria for determining which vaccines
recommended by ACIP for the U.S.
population will be required for
immigrants in accordance with section
212(a)(1)(A)(ii) of the Immigration and
Nationality Act, Section 212 (8 U.S.C.
1182(a)(1)(A)(ii)).
CDC will continue to work closely
with the Department of Homeland
Security and the Department of State in
the implementation of the vaccination
requirements for U.S. immigration
purposes.
DATES: Written comments must be
received on or before May 8, 2009.
Comments received after April 8, 2009
will be considered to the extent
possible.
1 For purposes of this Notice, ‘‘potential to cause
an outbreak’’ means the occurrence of more cases
of disease than could be anticipated in a given area
or among a specific group of people over a
particular period of time. In general, and as
observed through previous experience, an outbreak
is associated with a public health response.
PO 00000
Frm 00074
Fmt 4703
Sfmt 4703
ADDRESSES: You may submit written
comments to the following address:
Division of Global Migration and
Quarantine, Centers for Disease Control
and Prevention, U.S. Department of
Health and Human Services, Attn:
Immigration Vaccination Requirements,
1600 Clifton Road, NE., MS E–03,
Atlanta, Georgia, 30333.
You may also submit written
comments via e-mail to
DGMQpubliccomments@cdc.gov.
FOR FURTHER INFORMATION CONTACT:
David M. McAdam, Division of Global
Migration and Quarantine, Centers for
Disease Control and Prevention, U.S.
Department of Health and Human
Services, 1600 Clifton Road, NE., MS E–
03, Atlanta, Georgia 30333; telephone
404–498–1600.
SUPPLEMENTARY INFORMATION:
Background
Medical examinations for immigration
purposes are authorized under section
232 of the Immigration and Nationality
Act (INA) (8 U.S.C. 1222) Under
sections 212(a)(1) and 232 of the INA (8
U.S.C. 1182(a)(1) and 1222), and section
325 of the Public Health Service Act (42
U.S.C. 252), the Department of Health
and Human Services (HHS) establishes
requirements for the medical
examination. The Secretary of HHS has
delegated this authority to the Centers
for Disease Control and Prevention
(CDC), and it is administered by CDC’s
Division of Global Migration and
Quarantine (DGMQ). These
requirements are codified in 42 CFR
part 34, Medical Examination of Aliens.
Panel physicians and civil surgeons,
through contractual agreements and by
designations with the Department of
State and the Department of Homeland
Security, respectively, conduct the
medical examinations in accordance
with these regulations and as provided
for in Technical Instructions (TIs)
issued by CDC/DGMQ. The vaccination
requirements for U.S. immigration
purposes are listed in the Technical
Instructions (see https://www.cdc.gov/
ncidod/dq/technica.htm).
Under section 212(a)(1)(A)(ii) of the
Immigration and Nationality Act (8
U.S.C. 1182(a)(1)(A)(ii)), an alien who
seeks admission as an immigrant, or
who seeks adjustment of status to one
lawfully admitted for permanent
residence, must present documentation
for having received vaccination for
‘‘vaccine-preventable diseases, which
shall include at least the following
diseases: mumps, measles, rubella,
polio, tetanus and diphtheria toxoids,
pertussis, Haemophilus influenzae type
B and hepatitis B, and any other
E:\FR\FM\08APN1.SGM
08APN1
Agencies
[Federal Register Volume 74, Number 66 (Wednesday, April 8, 2009)]
[Notices]
[Pages 15985-15986]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-7941]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[Docket Number NIOSH-161]
Request for Information on Carbon Nanotubes (CNTs) Including
Single-Walled Carbon Nanotubes (SWCNTs) and Multi-Walled Carbon
Nanotubes (MWCNTs)
AGENCY: National Institute for Occupational Safety and Health (NIOSH)
of the Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice of public comment period.
-----------------------------------------------------------------------
SUMMARY: The National Institute for Occupational Safety and Health
(NIOSH) of the Centers for Disease Control and Prevention (CDC) intends
to evaluate the scientific data on carbon nanotubes (CNTs) and develop
appropriate communication documents, such as an Alert and/or Current
Intelligence Bulletin, which will convey the potential health risks and
recommend measures for the safe handling of these materials. NIOSH has
developed guidelines for managing the potential health concerns
associated with occupational exposures to engineered nanoparticles
[see: https://www.cdc.gov/niosh/topics/nanotech/safenano/] which will
provide the framework for developing specific recommendations for CNTs.
NIOSH is requesting information on the following: (1) Published and
unpublished reports and findings from in vitro and in vivo toxicity
studies with CNTs, (2) information on possible health effects observed
in workers exposed to CNTs, (3) information on workplaces and products
in which CNTs can be found, (4) description of work tasks and scenarios
with a potential for exposure, (5) workplace exposure data, and (6)
information on control measures (e.g., engineering controls, work
practices, personal protective equipment) that are being used in
workplaces where potential exposures to CNTs occur.
Public Comment Period: Comments must be received by May 15, 2009.
ADDRESSES: You may submit comments, identified by docket number NIOSH-
161, by any of the following methods:
Mail: NIOSH Docket Office, Robert A. Taft Laboratories,
MS-C34, 4676 Columbia Parkway, Cincinnati, OH 45226.
Facsimile: (513) 533-8285.
E-mail: nioshdocket@cdc.gov.
All information received in response to this notice will be
available for public examination and copying at the NIOSH Docket
Office, 4676 Columbia Parkway, Cincinnati, Ohio 45226. A complete
electronic docket containing all comments submitted will be available
on the NIOSH Web page at https://www.cdc.gov/niosh/docket, and comments
will be available in writing by request. NIOSH includes all comments
received without change in the docket, including any personal
information provided.
FOR FURTHER INFORMATION CONTACT: Ralph D. Zumwalde, NIOSH, Robert A.
Taft Laboratories, MS-C32, 4676 Columbia Parkway, Cincinnati, OH 45226,
telephone (513) 533-8320.
SUPPLEMENTARY INFORMATION: Nanotechnology is generally defined as the
intentional manipulation of matter to form novel structures with one or
more dimension or features less than 100 nanometers (nm).
Nanotechnology involves a wide range of chemistries and almost
unlimited types of structures that have highly unpredictable
interactions with biological systems. Carbon nanotubes (CNTs) are a
type of nanomaterial comprised of a sheet of graphite (a hexagonal
lattice of carbon) rolled into a cylinder that can have a length-to-
width ratio greater than 1,000. Carbon nanotubes are produced having a
single cylinder carbon wall (single-walled carbon nanotubes [SWCNT]) or
having multiple walls-cylinders nested within other cylinders (multi-
walled carbon nanotubes [MWCNT]). CNTs range in diameter from about 1-2
nanometers for SWCNTs to dozens of nanometers for MWCNTs with lengths
extending into the micrometer range.
There are several major techniques used in the synthesis of CNTs.
The arc-evaporation technique involves passing a current of about 50 A
between two graphite electrodes in an atmosphere of helium in the
presence of metal catalysts (Co, Ni). The second method is chemical
vapor deposition, where nanotubes are formed by decomposition of a
carbon-containing gas with use of nano-sized catalytic particles
usually Fe, Co, Yt or Ni. The advantage of catalytic synthesis over
arc-evaporation is the ability to scale-up for volume production. The
third method for making CNTs, laser ablation, involves employment of a
powerful laser to vaporize metal (Co and Ni)-graphite targets. Of the
three major processes, chemical vapor deposition is the most prominent
one that is currently used for CNT production.
Due to their unique physical and chemical properties, CNTs have
sparked much research into developing novel applications. CNTs are
ideal non-biodegradable materials; they are stronger then steel,
flexible, lightweight, heat resistant, and have high electrical
conductivity. The market for CNTs is estimated to grow substantially
over the next decade. They are currently used in a variety of
applications including: Electronics, reinforced plastics, micro-
fabrication conjugated polymer activators, biosensors, enhanced
electron/scanning microscopy imaging techniques, and in pharmaceutical/
biomedical devices for drug delivery and medical diagnostics. Estimates
of the number of workers potentially exposed to CNTs are unavailable
due to limited exposure data and its relatively recent introduction
into domestic commerce.
The toxic nature of SWCNTs and MWCNTs in humans is not known.
Recently published in vitro and in vivo studies with some SWCNTs and
MWCNTs describe adverse effects including their ability to be cytotoxic
when tested in various cell cultures, and cause acute inflammation and
early onset of fibrosis when delivered to the lungs of mice by
pharyngeal aspiration or inhalation. No occupational exposure limits
for CNTs have been established by NIOSH or the Occupational Safety and
Health Administration (OSHA).
NIOSH seeks to obtain materials, including published and
unpublished reports and research findings, to evaluate the possible
health risks of occupational exposure to CNTs. Examples of requested
information include, but not limited to, the following: (1)
Identification of industries or occupations in which exposures to CNTs
may occur.
(2) Trends in the production and use of CNTs.
(3) Description of work tasks and scenarios with a potential for
exposure to CNTs.
(4) Workplace exposure measurement data in various types of
industries and jobs.
(5) Case reports or other health information demonstrating
potential health effects in workers exposed to CNTs.
(6) Research findings from in vitro and in vivo toxicity studies.
[[Page 15986]]
(7) Information on control measures (e.g., engineering controls,
work practices, PPE) being taken to minimize worker exposure to CNTs.
Dated: March 31, 2009.
James D. Seligman,
Chief Information Officer, Centers for Disease Control and Prevention.
[FR Doc. E9-7941 Filed 4-7-09; 8:45 am]
BILLING CODE 4163-19-P